Stocks Roundup: Abbott Laboratories (ABT), Yahoo! Inc. (YHOO), eBay Inc. (EBAY)

Abbott Laboratories (ABT) grew with the stock adding 0.45% or $0.2 to close at $44.2 on light trading volume of 8.98M compared its three months average trading volume of 9.16M. The Abbott Park Illinois 60064 based company operating under the Medical Appliances & Equipment industry has been trending up for the last 52 weeks, with the shares price now 18.3% up for the period and up by 15.82% so far this year. With price target of $47.23 and a 22.54% rebound from 52-week low, Abbott Laboratories has plenty of upside potential, making it a hold with a view buy.

Abbott Laboratories manufactures and sells health care products worldwide. The company’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière’s disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; and influenza vaccines, as well as to regulate physiological rhythm of the colon. Its Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments to automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic-based tests; informatics and automation solutions; and instrument used to identify infection-causing pathogens. The company’s Nutritional Products segment provides pediatric and adult nutritional products. Its Vascular Products segment offers coronary, endovascular, vessel closure, and structural heart devices to treat vascular disease. The company also provides blood and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes; and medical devices for the eye, such as cataract and LASIK surgery, contact lens care, and dry eye products. In addition, it develops cardiovascular medical devices. It serves retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices, and government agencies. The company has strategic alliance with Fonterra. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

Yahoo! Inc. (YHOO) had a active trading with around 8.97M shares changing hands compared to its three month average trading volume of 8.82M. The stock traded between $45.01 and $45.69 before closing at the price of $45.16 with -1.07% change on the day. The Sunnyvale California 94089 based company is currently trading 61.63% above its 52 week low of $29.7 and -3.34% below its 52 week high of $46.72. Both the RSI indicator and target price of  and $46.76 respectively, lead us to believe that it could rise over the coming weeks.

Yahoo! Inc., together with its subsidiaries, provides search and display advertising services on Yahoo properties and affiliate sites worldwide. The company offers Yahoo Search that serves as a guide for users to discover information on the Internet; Yahoo Mail, which connects users to the people and content; and Yahoo Messenger, an instant messaging service, which enables users to connect, communicate, and share experiences in real-time. It also provides digital content products, including Yahoo News, which gives users to discover, consume, and engage around the news, content, and video; Yahoo Sports, which serves audiences of sports enthusiasts; Yahoo Finance that offers a range of financial data, information, and tools; Yahoo Lifestyle to engage users passionate about style and fashion; and Tumblr, which provides a Web platform and mobile applications on iOS and android to create, share, and curate content, as well as Tumblr messaging that enables users to engage with other users that share their same interests and passions. In addition, the company provides advertiser products, such as Yahoo Gemini, a marketplace for search and native advertising; and BrightRoll, which offers a suite of media-agnostic tools to enable advertisers, publishers, and partners connect with users across ad formats and devices. Further, it offers advertising formats; and digital advertising products, such as Yahoo native, Yahoo video, Yahoo premium, and Yahoo audience ads. Additionally, the company offers Yahoo Mobile Developer suite consisting of Flurry Analytics, Yahoo App Publishing, Yahoo App Marketing, and Tumblr In-App Sharing tools to measure, monetize, advertise, and improve their apps. Yahoo! Inc. was founded in 1994 and is headquartered in Sunnyvale, California.

eBay Inc. (EBAY) saw its value decrease by -1.38% as the stock dropped $-0.47 to finish the day at a closing price of $33.54. The stock was lighter in trading and has fluctuated between $22.3-$34.15 per share for the past year. The shares, which traded within a range of $33.46 to $34.15 during the day, are up by 17.73% in the past three months and up by 9.57% over the past six months. It is currently trading 4.45% above its 20 day moving average and 9.12% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $34.38 a share over the next twelve months. The current relative strength index (RSI) reading is 66.78.The technical indicator lead us to believe there will be no major movement any time soon, hold.

eBay Inc. operates commerce platforms that connect various buyers and sellers worldwide. Its platforms enable sellers to organize and offer their inventory for sale; and buyers to find and purchase it virtually. The company’s Marketplace platforms include its online marketplace at ebay.com and the eBay mobile apps; and StubHub platforms comprise its online ticket platform at stubhub.com, and the StubHub mobile apps and Ticketbis platforms that connect fans with their favorite sporting events, shows, and artists, as well as enables them to buy and sell tickets. Its Classifieds platforms include a collection of brands, such as mobile.de, Kijiji, Gumtree, Marktplaats, eBay Kleinanzeigen, and others, which offer online classifieds to enable people find whatever they are looking for in their local communities. The company’s platforms enable users to find, buy, sell, and pay for items through various online, mobile, and offline channels that include retailers, distributors, liquidators, import and export companies, auctioneers, catalog and mail-order companies, classifieds, directories, search engines, commerce participants, shopping channels, and networks. eBay Inc. was founded in 1995 and is headquartered in San Jose, California.

 

Stocks in the Spotlight: Weyerhaeuser Co. (WY), Red Hat, Inc. (RHT), Abbott Laboratories (ABT)

Weyerhaeuser Co. (WY) had a light trading with around 4.17M shares changing hands compared to its three month average trading volume of 4.29M. The stock traded between $32.97 and $33.57 before closing at the price of $33.29 with -1.48% change on the day. The Federal Way Washington 98003 based company is currently trading 53.08% above its 52 week low of $22.35 and -2.09% below its 52 week high of $34. Both the RSI indicator and target price of 63.81 and $34.46 respectively, lead us to believe that it should be put on hold over the coming weeks.

Weyerhaeuser Co. is a real estate investment trust. It primarily invests in United States. The firm operates under four business segments, timberlands, wood products, cellulose fibers and real estate. It owns timberlands primarily in the U.S and has long-term licenses in Canada. The firm manufactures wood and specialty cellulose fibers products, and develops real estate, primarily as a builder of single-family homes. Weyerhaeuser Co was founded in 1900 and is based in Seattle, Washington.

Red Hat, Inc. (RHT) continued its upward trend with the stock climbing 0.4% or $0.32 to close the day at $80.09 on light trading volume of 1.31M shares, compared to its three month average trading volume of 1.92M. The Raleigh North Carolina 27601 based company has been outperforming the application software group over the past 52 weeks, with the stock gaining 25.45%, compared to the industry which has advanced 29.41% over the same period. With RSI of 66.08, the stock should still continue to rise and get closer to its one year target estimate of $86.2, making it a hold for now.

Red Hat, Inc. provides open source software solutions to develop and offer operating system, virtualization, management, middleware, cloud, mobile, and storage technologies to various enterprises worldwide. It offers infrastructure-related solutions, such as Red Hat Enterprise Linux, an operating system platform that runs on hardware for use in physical, virtual, container, and cloud environments; Red Hat Satellite, a system management offering that helps to deploy and manage Red Hat infrastructure across physical and virtual servers, and cloud environments; and Red Hat Enterprise Virtualization, a software solution that allows customers to utilize and manage a common hardware infrastructure to run multiple operating systems and applications. The company offers application development-related and other technology solutions, such as Red Hat JBoss Middleware, a solution for developing, deploying, and managing applications, as well as integrating applications, data, and devices along with business processes automation; Red Hat cloud offerings, a software solution that enables customers to build and manage various cloud computing environments; Red Hat Mobile, a software development platform that enables customers to develop, integrate, deploy, and manage mobile applications for enterprises; and Red Hat Storage, a software solution that enables customers to treat physical server storage as a scalable, shared, centrally-managed pool of virtual storage and to manage large, unstructured, or semi-structured data in physical, virtual, and cloud environments. It also provides consulting, support, and training services; and real-time operating system, distributed computing, directory services, and user authentication. The company was formerly known as Red Hat Software, Inc. and changed its name to Red Hat, Inc. in June 1999. Red Hat, Inc. was founded in 1993 and is headquartered in Raleigh, North Carolina.

Abbott Laboratories (ABT) shares were up in last trading by 0.99% to $43.65. It experienced lighter than average volume on day. The stock increased in value by almost 1.77% over the past week and grew 6.65% in the past month. It is currently trading 9.27% above its 50 day moving average and 8.66% above its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -3.45% decrease in value from its one year high of $45.79. The RSI indicator value of 76.02, lead us to believe that it may reverse gains in the near term.

Abbott Laboratories manufactures and sells health care products worldwide. The company’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière’s disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; and influenza vaccines, as well as to regulate physiological rhythm of the colon. Its Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments to automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic-based tests; informatics and automation solutions; and instrument used to identify infection-causing pathogens. The company’s Nutritional Products segment provides pediatric and adult nutritional products. Its Vascular Products segment offers coronary, endovascular, vessel closure, and structural heart devices to treat vascular disease. The company also provides blood and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes; and medical devices for the eye, such as cataract and LASIK surgery, contact lens care, and dry eye products. In addition, it develops cardiovascular medical devices. It serves retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices, and government agencies. The company has strategic alliance with Fonterra. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

 

Three Movers to Watch for: T-Mobile US, Inc. (TMUS), PPL Corporation (PPL), Abbott Laboratories (ABT)

T-Mobile US, Inc. (TMUS) grew with the stock adding 0.22% or $0.14 to close at $62.39 on light trading volume of 3.8M compared its three months average trading volume of 4.12M. The Bellevue Washington 98006 based company operating under the Wireless Communications industry has been trending up for the last 52 weeks, with the shares price now 83.34% up for the period and up by 8.49% so far this year. With price target of $62.25 and a 85.68% rebound from 52-week low, T-Mobile US, Inc. has plenty of upside potential, making it a hold with a view buy.

T-Mobile US, Inc., together with its subsidiaries, provides mobile communications services for consumers and businesses in the United States, Puerto Rico, and the U.S. Virgin Islands. The company offers voice, messaging, and data services in the postpaid, prepaid, and wholesale markets. It also provides wireless devices, including smartphones, tablets, and other mobile communication devices, as well as accessories that are manufactured by various suppliers. The company offers services, devices, and accessories under the T-Mobile and MetroPCS brands through its owned and operated retail stores, as well as through its Websites. T-Mobile US, Inc. also sells its devices and accessories to dealers and other third party distributors for resale through independent third-party retail outlets and various third-party Websites. It delivers wireless services to approximately 65.5 million customers. The company was founded in 1994 and is headquartered in Bellevue, Washington. T-Mobile US, Inc. operates as a subsidiary of Deutsche Telekom Holding B.V.

PPL Corporation (PPL) gained $0.08 to close the day at a new closing price of $35.5, a 0.23% increase in value from its previous closing price that moved the stock 11.95% above its 52 week low of $32.08. A total of 3.71M shares exchanged hands during the day compared with its three month average trading volume of 3.79M. The stock, which fluctuated between $35.34 and $35.62 during the day, currently situated -9.06% below its 52 week high. The stock is up by 3.68% in the past one month and up by 6.95% over the past three months. With a one year target estimate of $36.83 and RSI of 63.51, the stock still has upside potential, making it a hold for now.

PPL Corporation, a utility company, delivers electricity and natural gas in the United States and the United Kingdom. It serves 322,000 natural gas and 403,000 electric customers in Louisville and adjacent areas in Kentucky; 543,000 customers in central, southeastern, and western Kentucky; and approximately 28,000 customers in 5 counties in southwestern Virginia, and fewer than 10 customers in Tennessee. The company also provides electric delivery services to approximately 1.4 million customers in Pennsylvania; and operates 4 electricity distribution networks in the United Kingdom, as well as delivers natural gas to customers in Kentucky; generates electricity from power plants in Kentucky; and sells wholesale electricity to 11 municipalities in Kentucky. In addition, it provides finance for the operations of PPL and subsidiaries. PPL Corporation was founded in 1920 and is headquartered in Allentown, Pennsylvania.

Abbott Laboratories (ABT) shares were up in last trading by 0.47% to $42.74. It experienced lighter than average volume on day. The stock decreased in value by almost -0.09% over the past week and grew 4.04% in the past month. It is currently trading 7.51% above its 50 day moving average and 6.44% above its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -5.46% decrease in value from its one year high of $45.79. The RSI indicator value of 68.9, lead us to believe that it is a hold for now.

Abbott Laboratories manufactures and sells health care products worldwide. The company’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière’s disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; and influenza vaccines, as well as to regulate physiological rhythm of the colon. Its Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments to automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic-based tests; informatics and automation solutions; and instrument used to identify infection-causing pathogens. The company’s Nutritional Products segment provides pediatric and adult nutritional products. Its Vascular Products segment offers coronary, endovascular, vessel closure, and structural heart devices to treat vascular disease. The company also provides blood and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes; and medical devices for the eye, such as cataract and LASIK surgery, contact lens care, and dry eye products. In addition, it develops cardiovascular medical devices. It serves retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices, and government agencies. The company has strategic alliance with Fonterra. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

 

Stocks Intraday Alert: Abbott Laboratories (ABT), First Data Corporation (FDC), Allergan plc (AGN)

Abbott Laboratories (ABT) failed to extend gains with the stock declining -1.14% or $-0.49 to close the day at $42.4 on lower than average trading volume of 6.72M shares, compared to its three month average trading volume of 9.45M. The Abbott Park Illinois 60064 based company has been outperforming the medical appliances & equipment companies by 7.0382% for last three months and its recent gains have pushed the stock slightly up 11.1% YTD, versus the medical appliances & equipment industry which is up 6.52% for the same period. The RSI of 67.14 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Abbott Laboratories manufactures and sells health care products worldwide. The company’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière’s disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; and influenza vaccines, as well as to regulate physiological rhythm of the colon. Its Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments to automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic-based tests; informatics and automation solutions; and instrument used to identify infection-causing pathogens. The company’s Nutritional Products segment provides pediatric and adult nutritional products. Its Vascular Products segment offers coronary, endovascular, vessel closure, and structural heart devices to treat vascular disease. The company also provides blood and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes; and medical devices for the eye, such as cataract and LASIK surgery, contact lens care, and dry eye products. In addition, it develops cardiovascular medical devices. It serves retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices, and government agencies. The company has strategic alliance with Fonterra. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

First Data Corporation (FDC) had a active trading with around 6.6M shares changing hands compared to its three month average trading volume of 3.99M. The stock traded between $15.02 and $15.45 before closing at the price of $15.15 with -2.26% change on the day. The Atlanta Georgia 30342 based company is currently trading 81% above its 52 week low of $8.37 and -5.96% below its 52 week high of $16.11. Both the RSI indicator and target price of 46.63 and $17.25 respectively, lead us to believe that it should be put on hold over the coming weeks.

First Data Corporation provides electronic commerce solutions for merchants, financial institutions, and card issuers worldwide. It operates through three segments: Global Business Solutions, Global Financial Solutions, and Network & Security Solutions. The Global Business Solutions segment offers retail point-of-sale merchant acquiring and e-commerce services; and next-generation offerings, such as mobile payment services and webstore-in-a-box solutions, as well as its cloud-based Clover point-of-sale operating system, which includes a marketplace for proprietary and third-party business applications. The Global Financial Solutions segment provides credit solutions for bank and non-bank issuers, including credit and retail private-label card processing solutions; and licensed financial software systems, such as VisionPLUS bank processing application and lending solutions. This segment also offers a suite of related services, including card personalization and embossing, statement printing, client service, and remittance processing services to financial institutions. The Network & Security Solutions segment provides various value-added solutions, which include electronic funds transfer network solutions, such as debit card processing solutions; stored value network solutions; and security and fraud management solutions. This segment also supports its online and mobile banking digital strategies, and its business supporting mobile wallets. First Data Corporation was founded in 1989 and is headquartered in Atlanta, Georgia.

Allergan plc (AGN) traded within a range of $231.53 to $243.8 after opening the day at $236.09. The company has seen its stock increase in value by 14.84% so far this year. The stock was up close to 3.68% on active volume in last trading session and closed at $241.17 per share. After the recent gain, the stock is currently holding -19.96% below its 52 week high of $301.32 and 30.72% above its 12-month low of $184.5. The shares are up by over 20.92% in the last three months, and the RSI indicator value of 80.18 is bearish. The technical indicator is offering a warning sign that the stock can’t keep current pace going.

Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Brands, US Medical Aesthetics, International Brands, and Anda Distribution segments. The company offers a portfolio of products that provide treatments for the central nervous system, gastroenterology, women’s health and urology, ophthalmology, neurosciences, medical aesthetics, liver disease, inflammation, fibrosis, and HIV, as well as dermatology and plastic surgery, and Alzheimer’s disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, it distributes generic and branded pharmaceutical products primarily to independent pharmacies, pharmacy chains, pharmacy buying groups, and physicians’ offices. Allergan plc has a collaboration with T2 Biosystems to develop blood-based diagnostic panel for the detection of Gram-negative bacterial species. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

 

Investor’s Alert: Abbott Laboratories (ABT), Kinder Morgan, Inc. (KMI), Activision Blizzard, Inc. (ATVI)

Abbott Laboratories (ABT) failed to extend gains with the stock declining -0.82% or $-0.35 to close the day at $42.43 on lower than average trading volume of 8.69M shares, compared to its three month average trading volume of 9.4M. The Abbott Park Illinois 60064 based company has been outperforming the medical appliances & equipment companies by 11.2176% for last three months and its recent gains have pushed the stock slightly up 11.18% YTD, versus the medical appliances & equipment industry which is up 6.63% for the same period. The RSI of 73.49 indicates the stock is overbought at the current levels, sell for now.

Abbott Laboratories manufactures and sells health care products worldwide. The company’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière’s disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; and influenza vaccines, as well as to regulate physiological rhythm of the colon. Its Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments to automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic-based tests; informatics and automation solutions; and instrument used to identify infection-causing pathogens. The company’s Nutritional Products segment provides pediatric and adult nutritional products. Its Vascular Products segment offers coronary, endovascular, vessel closure, and structural heart devices to treat vascular disease. The company also provides blood and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes; and medical devices for the eye, such as cataract and LASIK surgery, contact lens care, and dry eye products. In addition, it develops cardiovascular medical devices. It serves retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices, and government agencies. The company has strategic alliance with Fonterra. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

Kinder Morgan, Inc. (KMI) had a active trading with around 8.49M shares changing hands compared to its three month average trading volume of 13.18M. The stock traded between $22.47 and $22.97 before closing at the price of $22.5 with -1.92% change on the day. The Houston Texas 77002 based company is currently trading 73.91% above its 52 week low of $13.26 and -2.56% below its 52 week high of $23.36. Both the RSI indicator and target price of 57.35 and $25.5 respectively, lead us to believe that it should be put on hold over the coming weeks.

Kinder Morgan, Inc. operates as an energy infrastructure company in North America. It operates through Natural Gas Pipelines, CO2, Terminals, Products Pipelines, Kinder Morgan Canada, and Other segments. The Natural Gas Pipelines segment owns and operates interstate and intrastate natural gas pipeline and storage systems; natural gas and crude oil gathering systems, and natural gas processing and treating facilities; natural gas liquids fractionation facilities and transportation systems; and liquefied natural gas facilities. The CO2 segment produces, transports, and markets CO2 for use in enhanced oil recovery projects; and owns interests in oil-producing fields, gas processing plants, and crude oil pipelines in the Permian Basin region of West Texas. The Terminals segment owns and operates liquids and bulk terminals that transload and store refined petroleum products, crude oil, and condensate, as well as bulk products, including coal, petroleum coke, cement, alumina, salt, and other bulk chemicals; and owns and operates tankers. The Products Pipelines segment owns and operates refined petroleum products, and crude oil and condensate pipelines; and associated product terminals and petroleum pipeline transmix facilities. The Kinder Morgan Canada segment owns and operates Trans Mountain pipeline system that transports crude oil and refined petroleum products from Edmonton, Alberta, and Canada to marketing terminals and refineries in British Columbia, Canada, and Washington; and jet fuel aviation turbine fuel pipeline that serves the Vancouver (Canada) International Airport. The Other segment includes various physical natural gas contracts with power plants. Kinder Morgan, Inc. owns interests in or operates approximately 84,000 miles of pipelines and 180 terminals. The company was formerly known as Kinder Morgan Holdco LLC and changed its name to Kinder Morgan, Inc. in February 2011. Kinder Morgan, Inc. was founded in 1936 and is headquartered in Houston, Texas.

Activision Blizzard, Inc. (ATVI) traded within a range of $39.65 to $40.22 after opening the day at $40.04. The company has seen its stock increase in value by 11.3% so far this year. The stock was up close to 0.45% on light volume in last trading session and closed at $40.19 per share. After the recent gain, the stock is currently holding -11.77% below its 52 week high of $45.55 and 52.95% above its 12-month low of $26.49. The shares are down by over -7.33% in the last three months, and the RSI indicator value of 66.94 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Activision Blizzard, Inc. develops and publishes online, personal computer (PC), video game console, handheld, mobile, and tablet games. The company operates through two segments, Activision Publishing, Inc. and Blizzard Entertainment, Inc. The company develops, publishes, and sells interactive software products and content through retail channels or digital downloads; and downloadable content to a range of gamers. It also publishes subscription-based massively multiplayer online role-playing games; and strategy and role-playing games. In addition, the company maintains a proprietary online gaming service, Battle.net that facilitates the creation of user generated content, digital distribution, and online social connectivity in its games. Further, it engages in creating original film and television content; and provides warehousing, logistical, and sales distribution services to third-party publishers of interactive entertainment software, as well as manufacturers of interactive entertainment hardware products. The company serves retailers and distributors, including mass-market retailers, consumer electronics stores, discount warehouses, game specialty stores, and consumers through third-party distribution, licensing arrangements, and direct digital purchases in the United States, Canada, Canada, the United Kingdom, France, Germany, Ireland, Italy, Sweden, Spain, the Netherlands, Australia, South Korea, China, and internationally. Activision Blizzard, Inc. is headquartered in Santa Monica, California.

 

Eye Catching Stocks: Abbott Laboratories (ABT), General Motors Company (GM), Morgan Stanley (MS)

Abbott Laboratories (ABT) continued its upward trend with the stock climbing 0.99% or $0.42 to close the day at $42.75 on light trading volume of 11.84M shares, compared to its three month average trading volume of 9.26M. The Abbott Park Illinois 60064 based company has been outperforming the medical appliances & equipment group over the past 52 weeks, with the stock gaining 15.29%, compared to the industry which has advanced 15.36% over the same period. With RSI of 81.5, the stock should still continue to rise and get closer to its one year target estimate of $46.85, making it a hold for now.

Abbott Laboratories manufactures and sells health care products worldwide. The company’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière’s disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; and influenza vaccines, as well as to regulate physiological rhythm of the colon. Its Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments to automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic-based tests; informatics and automation solutions; and instrument used to identify infection-causing pathogens. The company’s Nutritional Products segment provides pediatric and adult nutritional products. Its Vascular Products segment offers coronary, endovascular, vessel closure, and structural heart devices to treat vascular disease. The company also provides blood and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes; and medical devices for the eye, such as cataract and LASIK surgery, contact lens care, and dry eye products. In addition, it develops cardiovascular medical devices. It serves retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices, and government agencies. The company has strategic alliance with Fonterra. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

General Motors Company (GM) fell -1.13% during last trading as the stock lost $-0.41 to finish the day at $35.73 with about 11.72M shares changing hands, compared to its three month average trading volume of 14.64M. The $54.46B market cap company, which fluctuated between $35.47 and $36.14 during the day, currently situated 40.43% above its 52 week low of $26.69 and -6.9% away from its one year high of $38.38. The RSI of 43.81 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

General Motors Company designs, builds, and sells cars, crossovers, trucks, and automobile parts worldwide. The company operates through GM North America, GM Europe, GM International Operations, GM South America, and GM Financial segments. It markets its vehicles primarily under the Buick, Cadillac, Chevrolet, GMC, Opel, Holden, Vauxhall, Baojun, Jiefang, and Wuling brand names. The company also sells cars and trucks to dealers for consumer retail sales, as well as to fleet customers, including daily rental car companies, commercial fleet customers, leasing companies, and governments. In addition, it offers connected safety, security and mobility solutions, and information technology services. The company, through its subsidiary, General Motors Financial Company, Inc., provides automotive financing services. General Motors Company was founded in 1897 and is based in Detroit, Michigan.

Morgan Stanley (MS) saw its value decrease by -1.33% as the stock dropped $-0.57 to finish the day at a closing price of $42.13. The stock was lighter in trading and has fluctuated between $21.16-$44.6 per share for the past year. The shares, which traded within a range of $41.83 to $42.51 during the day, are up by 26.87% in the past three months and up by 49.81% over the past six months. It is currently trading -1.91% below its 20 day moving average and -0.67% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $47.19 a share over the next twelve months. The current relative strength index (RSI) reading is 45.8. The technical indicator lead us to believe there will be no major movement any time soon, hold.

Morgan Stanley, a financial holding company, provides various financial products and services to corporations, governments, financial institutions, and individuals worldwide. The company’s Institutional Securities segment offers capital raising and financial advisory services, including services related to the underwriting of debt, equity, and other securities, as well as advice on mergers and acquisitions, restructurings, real estate, and project finance. This segment also provides sales and trading services, such as sales, financing, and market-making services in equity securities and fixed income products, including foreign exchange and commodities, as well as prime brokerage services; and corporate lending services, credit products, and investments and research services. Its Wealth Management segment offers various financial services and solutions covering brokerage and investment advisory services, market-making services in fixed income securities, financial and wealth planning services, annuity and insurance products, credit and other lending products, and banking and retirement plan services to individual investors, small-to-medium sized businesses, and institutions. The company’s Investment Management segment provides various investment strategies and products comprising asset management, including equity, fixed income, liquidity, alternatives, and managed futures products. This segment is also involved in merchant banking and real estate investing businesses. Morgan Stanley was founded in 1924 and is headquartered in New York, New York.

 

Three Movers to Watch for: Abbott Laboratories (ABT), Zimmer Biomet Holdings, Inc. (ZBH), KKR & Co. L.P. (KKR)

Abbott Laboratories (ABT) grew with the stock adding 1.85% or $0.76 to close at $41.77 on light trading volume of 12.32M compared its three months average trading volume of 9.13M. The Abbott Park Illinois 60064 based company operating under the Medical Appliances & Equipment industry has been trending up for the last 52 weeks, with the shares price now 11.39% up for the period and up by 9.45% so far this year. With price target of $46.85 and a 18.9% rebound from 52-week low, Abbott Laboratories has plenty of upside potential, making it a hold with a view buy.

Abbott Laboratories manufactures and sells health care products worldwide. The company’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière’s disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; and influenza vaccines, as well as to regulate physiological rhythm of the colon. Its Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments to automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic-based tests; informatics and automation solutions; and instrument used to identify infection-causing pathogens. The company’s Nutritional Products segment provides pediatric and adult nutritional products. Its Vascular Products segment offers coronary, endovascular, vessel closure, and structural heart devices to treat vascular disease. The company also provides blood and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes; and medical devices for the eye, such as cataract and LASIK surgery, contact lens care, and dry eye products. In addition, it develops cardiovascular medical devices. It serves retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices, and government agencies. The company has strategic alliance with Fonterra. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

Zimmer Biomet Holdings, Inc. (ZBH) gained $2.94 to close the day at a new closing price of $118.33, a 2.55% increase in value from its previous closing price that moved the stock 35.21% above its 52 week low of $88.27. A total of 2.96M shares exchanged hands during the day compared with its three month average trading volume of 2.06M. The stock, which fluctuated between $115.86 and $120.41 during the day, currently situated -10.96% below its 52 week high. The stock is up by 14.33% in the past one month and down by -3.22% over the past three months. With a one year target estimate of $130.6 and RSI of 73.36, the stock still has upside potential, making it a sell for now.

Zimmer Biomet Holdings, Inc., together with its subsidiaries, provides musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates through four segments: Americas Spine, Bone Healing, Craniomaxillofacial and Thoracic (CMF), and Dental. It designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip reconstructive products; S.E.T. products, including surgical, sports medicine, biologics, foot and ankle, extremities, and trauma products; dental products that include dental reconstructive implants, and dental prosthetic and regenerative products; and spine products comprising medical devices and surgical instruments. The company also offers face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. In addition, it provides bone cement and bone healing products. The company’s products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopaedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

KKR & Co. L.P. (KKR) shares were down in last trading by -1.03% to $17.36. It experienced lighter than average volume on day. The stock decreased in value by almost -1.48% over the past week and grew 12.22% in the past month. It is currently trading 5.77% above its 50 day moving average and 21.04% above its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -2.8% decrease in value from its one year high of $17.86. The RSI indicator value of 59.98, lead us to believe that it is a hold for now.

KKR & Co. L.P. is a private equity and real estate investment firm specializing in direct and fund of fund investments. It specializes in acquisitions, leveraged buyouts, management buyouts, credit special situations, growth equity, mature, mezzanine, distressed, and middle market investments. The firm considers investments in all industries with a focus on software, security, semiconductors, consumer electronics, internet of things (iot), internet, information services, content, technology and hardware, energy and infrastructure, real estate, services industry with a focus on business services, intelligence, industry-leading franchises and companies in natural resource, containers and packaging, agriculture, airports, ports, forestry, electric utilities, textiles, apparel and luxury goods, household durables, digital media, insurance, brokerage houses, non-durable goods distribution, supermarket retailing, grocery stores, food, beverage, and tobacco, hospitals, entertainment venues and production companies, publishing, printing services, capital goods, financial services, specialized finance, pipelines, and renewable energy. In energy and infrastructure, it focuses on the Upstream Oil and Gas and Equipment and Services verticals. In real estate, the firm seeks to invest in private and public real estate securities including property-level equity, debt and special situations transactions and businesses with significant real estate holdings, and oil and natural gas properties. The firm also invests in asset services sector that encompasses a broad array of B2B, B2C and B2G services verticals including asset-based, transport, logistics, leisure/hospitality, resource and utility support, infra-like, mission-critical, and environmental services. Within Americas, the firm prefers to invest in consumer products; chemicals, metals and mining; energy and natural resources; financial services; healthcare; industrials; media and communications; retail; and technology. Within Europe, the firm invests in consumer and retail; energy; financial services; health care; industrials and chemicals; media and digital; and telecom and technologies. Within Asia, it invests in consumer products; energy and resources; financial services; healthcare; industrials; logistics; media and telecom; retail; real estate; and technology. The firm seeks to invest in mid to high-end residential developments, but can invest in other projects throughout Mainland China through outright ownership, joint ventures, and merger. It invests globally with a focus on Australia, emerging and developed Asia, Middle East and Africa, Nordic, Southeast Asia, Asia Pacific, Ireland, Hong Kong, Japan, Taiwan, India, Vietnam, Indonesia, France, Germany, Netherlands, United Kingdom, Caribbean, Mexico, South America, North America, Brazil, Latin America, Korea, and United States of America. In the United States and Europe, the firm focuses on buyouts of large, publicly traded companies. It seeks to invest $30 million to $717 million in companies with enterprise values between $500 million to $2389 million. The firm prefers to invest in a range of debt and public equity investing and may co-invest. It seeks a board seat in its portfolio companies and a controlling ownership of a company or a strategic minority positions. The firm may acquire minority equity interests, particularly when making private equity investments in Asia or sponsoring investments as part of a large investor consortium. The firm typically holds its investment for a period of five to seven years and more and exits through initial public offerings, secondary offerings, and sales to strategic buyers. KKR & Co. L.P. was founded in 1976 and is based in New York, New York with additional offices across North America, Europe, Australia, and Asia.

 

Traders Watch list: Abbott Laboratories (ABT), Gilead Sciences Inc. (GILD), Halliburton Company (HAL)

Abbott Laboratories (ABT) saw its value increase by 0.1% as the stock gained $0.04 to finish the day at a closing price of $41. The stock was lighter in trading and has fluctuated between $36.02-$45.79 per share for the past year. The shares, which traded within a range of $40.9 to $41.31 during the day, are up by 3.27% in the past three months and down by -6.58% over the past six months. It is currently trading 2.4% above its 20 day moving average and 4.74% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $46.85 a share over the next twelve months. The current relative strength index (RSI) reading is 67.23.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Abbott Laboratories manufactures and sells health care products worldwide. The company’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière’s disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; and influenza vaccines, as well as to regulate physiological rhythm of the colon. Its Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments to automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic-based tests; informatics and automation solutions; and instrument used to identify infection-causing pathogens. The company’s Nutritional Products segment provides pediatric and adult nutritional products. Its Vascular Products segment offers coronary, endovascular, vessel closure, and structural heart devices to treat vascular disease. The company also provides blood and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes; and medical devices for the eye, such as cataract and LASIK surgery, contact lens care, and dry eye products. In addition, it develops cardiovascular medical devices. It serves retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices, and government agencies. The company has strategic alliance with Fonterra. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

Gilead Sciences Inc. (GILD) shares were up in last trading by 0.06% to $71.26. It experienced lighter than average volume on day. The stock increased in value by almost 0.35% over the past week and fell -3.35% in the past month. It is currently trading -3.12% below its 50 day moving average and -10.22% below its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -29.62% decrease in value from its one year high of $103.1. The RSI indicator value of 41.6, lead us to believe that it is a hold for now.

Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

Halliburton Company (HAL) traded within a range of $57.75 to $58.47 after opening the day at $57.94. The company has seen its stock increase in value by 7.62% so far this year. The stock was up close to 0.26% on light volume in last trading session and closed at $58.21 per share. After the recent gain, the stock is currently holding -0.97% below its 52 week high of $58.78 and 111.81% above its 12-month low of $27.96. The shares are up by over 22.65% in the last three months, and the RSI indicator value of 67.4 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Halliburton Company provides a range of services and products to the upstream oil and natural gas industry worldwide. The company’s Completion and Production segment offers production enhancement services, including stimulation and sand control services; and cementing services, such as bonding the well, well casing, and casing equipment. It also provides completion tools that offer downhole solutions and services, including well completion products and services, intelligent well completions, liner hanger systems, sand control systems, and service tools; pressure control services comprising coiled tubing, hydraulic workover units, and downhole tools; and pipeline and process services, such as pre-commissioning and maintenance, subsea pipeline, conventional pipeline, and process services. In addition, this segment offers oilfield production and completion chemicals and services; electrical submersible pumps and progressive cavity pumps; and installation, maintenance, repair, and testing services. The company’s Drilling and Evaluation segment provides drilling fluid systems, performance additives, completion fluids, solids control, specialized testing equipment, and waste management services; and drilling systems and services. It also offers wireline and perforating services that include open-hole logging, cased-hole and slickline, borehole seismic, and formation and reservoir solutions; and drill bits and services comprising roller cone rock bits, fixed cutter bits, hole enlargement, and related downhole tools and services, as well as coring equipment and services. In addition, this segment offers integrated exploration, drilling, and production software, as well as related professional and data management services; testing and subsea services, such as acquisition and analysis of reservoir information and optimization solutions; and oilfield project management and integrated solutions. Halliburton Company was founded in 1919 and is based in Houston, Texas.

 

Stocks in the Spotlight: JPMorgan Chase & Co. (JPM), Textron Inc. (TXT), Abbott Laboratories (ABT)

JPMorgan Chase & Co. (JPM) had a light trading with around 17.52M shares changing hands compared to its three month average trading volume of 18.23M. The stock traded between $85.17 and $86.17 before closing at the price of $86.03 with 1.55% change on the day. The New York New York 10017 based company is currently trading 68.5% above its 52 week low of $52.5 and -2.43% below its 52 week high of $88.17. Both the RSI indicator and target price of 58.84 and $88.93 respectively, lead us to believe that it should be put on hold over the coming weeks.

JPMorgan Chase & Co. operates as a financial services company worldwide. It operates through Consumer & Community Banking, Corporate & Investment Bank, Commercial Banking, and Asset Management segments. The Consumer & Community Banking segment offers deposit and investment products and services to consumers; lending, deposit, and cash management and payment solutions to small businesses; residential mortgages and home equity loans; and credit cards, payment services, payment processing services, auto loans and leases, and student loans. The Corporate & Investment Bank segment provides investment banking products and services, including advising on corporate strategy and structure, capital-raising in equity and debt markets, as well as loan origination and syndication; treasury services, such as cash management and liquidity solutions; and cash securities and derivative instruments, risk management solutions, prime brokerage, and research services. It also offers securities services, including custody, fund accounting and administration, and securities lending products for asset managers, insurance companies, and public and private investment funds. The Commercial Banking segment offers financial solutions, including lending, treasury, investment banking, and asset management to corporations, municipalities, financial institutions, and nonprofit entities, as well as financing to real estate investors and owners. The Asset Management segment provides investment and wealth management services across various asset classes, such as equities, fixed income, alternatives, and money market funds; multi-asset investment management services; retirement services; and brokerage and banking services comprising trusts, estates, loans, mortgages, and deposits. It has a strategic relationship with InvestCloud for the development of new digital capabilities for individual investors. JPMorgan Chase & Co. was founded in 1799 and is headquartered in New York, New York.

Textron Inc. (TXT) failed to extend gains with the stock declining -5.37% or $-2.65 to close the day at $46.73 on active trading volume of 16.89M shares, compared to its three month average trading volume of 1.46M. The Providence Rhode Island 02903 based company has been outperforming the aerospace/defense – major diversified group over the past 52 weeks, with the stock gaining 24.11%, compared to the industry which has advanced 27.25% over the same period. With RSI of 35.76, the stock should still continue to rise and get closer to its one year target estimate of $53, making it a hold for now.

Textron Inc. operates in the aircraft, defense, industrial, and finance businesses worldwide. It operates through five segments: Textron Aviation, Bell, Textron Systems, Industrial, and Finance. The Textron Aviation segment manufactures and sells business jets, turboprop aircraft, piston engine aircraft, and military trainer and defense aircraft; and commercial parts, as well as provides maintenance, inspection, and repair services. The Bell segment provides military and commercial helicopters, tiltrotor aircraft, and related spare parts and services. The Textron Systems segment produces unmanned aircraft systems; smart weapons, airborne and ground-based sensors and surveillance systems, and protection systems; armored vehicles, turrets, and related subsystems, as well as marine craft; test equipment and electronic warfare test, and training solutions; piston aircraft engines; and intelligence software solutions. This segment also designs, develops, manufactures, installs, and maintains full flight simulators, as well as offers training services. The Industrial segment offers blow-molded plastic fuel systems, windshield and headlamp washer systems, catalytic reduction systems, and engine camshafts, as well as plastic bottles and containers; golf cars, off-road utility and light transportation vehicles, aviation ground support equipment, professional turf-maintenance equipment, and turf-care vehicles; and powered equipment, electrical test and measurement instruments, mechanical and hydraulic tools, cable connectors, fiber optic assemblies, underground and aerial transmission and distribution products, and power utility products used in the construction, maintenance, telecommunications, data communications, electrical, utility, and plumbing industries. The Finance segment provides financing to purchase new and pre-owned aircrafts and helicopters. Textron Inc. was founded in 1923 and is headquartered in Providence, Rhode Island.

Abbott Laboratories (ABT) shares were down in last trading by 0% to $40.31. It experienced higher than average volume on day. The stock decreased in value by almost -1.1% over the past week and grew 5.96% in the past month. It is currently trading 3.03% above its 50 day moving average and 0.27% above its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -10.84% decrease in value from its one year high of $45.79. The RSI indicator value of 58.79, lead us to believe that it is a hold for now.

Abbott Laboratories manufactures and sells health care products worldwide. The company’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière’s disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; and influenza vaccines, as well as to regulate physiological rhythm of the colon. Its Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments to automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic-based tests; informatics and automation solutions; and instrument used to identify infection-causing pathogens. The company’s Nutritional Products segment provides pediatric and adult nutritional products. Its Vascular Products segment offers coronary, endovascular, vessel closure, and structural heart devices to treat vascular disease. The company also provides blood and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes; and medical devices for the eye, such as cataract and LASIK surgery, contact lens care, and dry eye products. In addition, it develops cardiovascular medical devices. It serves retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices, and government agencies. The company has strategic alliance with Fonterra. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

 

Trader’s Round Up: Abbott Laboratories (ABT), Netflix, Inc. (NFLX), Coty Inc. (COTY)

Abbott Laboratories (ABT) retreated with the stock falling -0.07% or $-0.03 to close at $40.31 on light trading volume of 7.77M compared its three months average trading volume of 8.89M. The Abbott Park Illinois 60064 based company operating under the Medical Appliances & Equipment industry has been trending up for the last 52 weeks, with the shares price now 4.21% up for the period and up by 5.62% so far this year. With price target of $46.69 and a 14.81% rebound from 52-week low, Abbott Laboratories has plenty of upside potential, making it a hold with a view buy.

Abbott Laboratories manufactures and sells health care products worldwide. The company’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière’s disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; and influenza vaccines, as well as to regulate physiological rhythm of the colon. Its Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments to automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic-based tests; informatics and automation solutions; and instrument used to identify infection-causing pathogens. The company’s Nutritional Products segment provides pediatric and adult nutritional products. Its Vascular Products segment offers coronary, endovascular, vessel closure, and structural heart devices to treat vascular disease. The company also provides blood and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes; and medical devices for the eye, such as cataract and LASIK surgery, contact lens care, and dry eye products. In addition, it develops cardiovascular medical devices. It serves retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices, and government agencies. The company has strategic alliance with Fonterra. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

Netflix, Inc. (NFLX) gained $2.72 to close the day at a new closing price of $140.11, a 1.98% increase in value from its previous closing price that moved the stock 75.25% above its 52 week low of $79.95. A total of 7.74M shares exchanged hands during the day compared with its three month average trading volume of 7.54M. The stock, which fluctuated between $137.03 and $140.93 during the day, currently situated -2.34% below its 52 week high. The stock is up by 10.76% in the past one month and up by 9.89% over the past three months. With a one year target estimate of $144.4 and RSI of 73.41, the stock still has upside potential, making it a sell for now.

Netflix, Inc., an Internet television network, engages in the Internet delivery of television (TV) shows and movies on various Internet-connected screens. The company operates in three segments: Domestic streaming, International streaming and Domestic DVD. It offer members with the ability to receive TV shows and movies streaming content, including original series, documentaries, and feature films through a host of Internet-connected screens, such as TVs, digital video players, TV set-top boxes, and mobile devices. The company also provides DVDs-by-mail membership services. As of October 17, 2016, it served approximately 86 million streaming members in 190 countries. Netflix, Inc. was founded in 1997 and is headquartered in Los Gatos, California.

Coty Inc. (COTY) shares were up in last trading by 1.28% to $19. It experienced higher than average volume on day. The stock decreased in value by almost -0.52% over the past week and grew 1.28% in the past month. It is currently trading 1.32% above its 50 day moving average and -21.05% below its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -38.87% decrease in value from its one year high of $31.6. The RSI indicator value of 51.86, lead us to believe that it is a hold for now.

Coty Inc., together with its subsidiaries, manufactures, markets, and distributes beauty products worldwide. The company operates through four segments: Fragrances, Color Cosmetics, Skin & Body Care, and Brazil Acquisition. It offers fragrances under the Calvin Klein, Marc Jacobs, Davidoff, Chloé, Balenciaga, Beyoncé, Bottega Veneta, Guess?, Katy Perry, Miu Miu, and Roberto Cavalli brand names. The company also provides lip, eye, nail, and facial color products under the Bourjois, Rimmel, Sally Hansen, and OPI brands. In addition, it offers shower gels, deodorants, skin care, and sun treatment products under the adidas, Lancaster, philosophy, and Playboy brand names; and hair straighteners, hair dryers, curlers, and hair brushes; and spray, serum, cream, and foam product lines to curl, fix, protect, shine, straighten, and volumize hair. The company also markets its products under the Astor, Coty, Joop!, Jovan, Manhattan, and N.Y.C. New York Color brands. It sells its products through retailers, including hypermarkets, supermarkets, independent and chain drug stores and pharmacies, upscale perfumeries, upscale and mid-tier department stores, nail salons, specialty retailers, duty-free shops and traditional food, and drug and mass retailers. Coty Inc. was founded in 1904 and is headquartered in New York, New York.